- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 699KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 306KB)
Dapagliflozin with sitagliptin – March 2024
Dapagliflozin with Sitagliptin: Tablet containing dapagliflozin 10 mg with sitagliptin 100 mg; Sidapvia®
Last updated
30 May 2025